Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-RIC
NCT03821610Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Nov 2018
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by University of Birmingham. Primary endpoint: Disease Free Survival at 2 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
cyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03821610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821610.